We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Venture Life Group Plc | LSE:VLG | London | Ordinary Share | GB00BFPM8908 | ORD 0.3P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 50.50 | 180,880 | 08:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 50.00 | 51.00 | 50.50 | 50.50 | 50.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Misc Retail Stores, Nec | 51.41M | 921k | 0.0072 | 70.14 | 64.16M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:40:09 | O | 125,000 | 50.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 05/6/2025 | 14:19 | UK RNS | Venture Life Group PLC Notice of Annual General Meeting |
| 19/5/2025 | 14:52 | ALNC |  Venture Life chair to remain as conflict of interest no longer exists |
| 19/5/2025 | 07:01 | UK RNS | Venture Life Group PLC Director Dealings |
| 19/5/2025 | 07:00 | UK RNS | Venture Life Group PLC Board Update |
| 12/5/2025 | 13:56 | ALNC | Venture Life shares rise on CDMO business, non-core products disposal |
| 12/5/2025 | 10:50 | ALNC | AIM WINNERS & LOSERS: Mycelx loss narrows despite revenue slump |
| 12/5/2025 | 08:49 | UK RNS | Venture Life Group PLC Replacement: Cash sale of CDMO operations |
| 12/5/2025 | 07:00 | UK RNS | Venture Life Group PLC Cash sale of CDMO operations |
| 28/4/2025 | 10:50 | UK RNS | Venture Life Group PLC Holding(s) in Company |
| 08/4/2025 | 16:53 | UK RNS | Venture Life Group PLC Holding(s) in Company |
Venture Life (VLG) Share Charts1 Year Venture Life Chart |
|
1 Month Venture Life Chart |
Intraday Venture Life Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 18/6/2025 | 09:59 | Venture Life Group plc | 2,090 |
| 20/3/2024 | 22:22 | ValueGrowth Investing | 35,074 |
| 02/4/2015 | 10:58 | Venture Life Group - Intro video | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:06:43 | 50.00 | 125,000 | 62,500.00 | O |
| 15:40:10 | 50.00 | 10,000 | 5,000.00 | O |
| 15:40:10 | 50.00 | 10,000 | 5,000.00 | O |
| 11:23:57 | 50.00 | 9,878 | 4,939.10 | O |
| 11:08:46 | 50.40 | 6,000 | 3,024.00 | O |
| Top Posts |
|---|
Posted at 20/6/2025 09:20 by Venture Life Daily Update Venture Life Group Plc is listed in the Misc Retail Stores, Nec sector of the London Stock Exchange with ticker VLG. The last closing price for Venture Life was 50.50p.Venture Life currently has 127,052,312 shares in issue. The market capitalisation of Venture Life is £64,161,418. Venture Life has a price to earnings ratio (PE ratio) of 70.14. This morning VLG shares opened at 50.50p |
Posted at 02/6/2025 12:13 by eagle eye FY results to Dec 24 due in a few weeks, which should give an update on H1 and outlook for H2.Foundations are being put in place to scale this business into a much bigger organization. VLG will have a strong balance sheet with plenty of firepower. It is also small enough to make acquisitions that will move the dial. |
Posted at 15/5/2025 11:36 by rivaldo Cavendish have updated their forecasts to account for the disposal and the ongoing business.They have a 100p price target. They forecast 4.2p EPS this year rising to 5.8p EPS next year and then 7.1p EPS. They also see £32.8m cash pile at the end of this year, rising to £41.1m and then £51.2m - respectively 52%, 65% and 81% of the current £63.3m m/cap. Cavendish summarise as follows (extracts): "Pure play consumer healthcare Venture Life has announced the disposal of its contract development and manufacturing organisation (CDMO) along with some non-core brands. The acquiror, Italian-based BioDue, will pay €62m (c£53m), indicating an EV/Sales multiple of 2.6x, which we believe represents excellent value for Venture Life. Post-sale, Venture Life will become a focused pure play consumer health business, which we expect to deliver revenues of c£43m and EBITDA of c£7.7m in FY25, before re-deployment of proceeds into new opportunities. The cash consideration will be used to pay down existing debt on completion and strengthen the company’s balance sheet to progress its established M&A strategy. On a continuing basis, we estimate the company will trade on c0.6x sales, at the current market value, which we believe presents an attractive level to acquire shares in the business. —Sale: Venture Life has announced the sale of its CDMO and certain peripheral brands to BioDue, a CDMO based in Italy. BioDue will pay a cash consideration of c€62m for these assets on a cash-free, debt-free basis, with completion expected to take place in 3Q25. Upon completion, Venture Life will enter a long-term development and manufacturing agreement with BioDue for an initial term of 10years and will retain a perpetual, exclusive and royalty licence to the relevant technical files. We calculate an FY24E acquisition sales multiple of 2.6x and EBITDA multiple of 10.8x." "—Forecasts: Our FY25 onwards forecasts are shown on a ‘locked-box —Valuation: Post-sale, we estimate that VLG will trade at 0.6x EV/Sales and 3.2x EV/EBITDA (FY25E), which are clearly attractive multiples. Our target valuation for the shares is based upon the valuation of Alliance Pharma, and we set our target price to £1 based upon this methodology. —Investment thesis: Post-sale, Venture Life will have a significantly simplified and more focused business, with a strong balance sheet. Operationally, the sale will reduce the company’s capital expenditures, improving cash conversion, which – along with the consideration – will allow the company to progress its organic and M&A strategies. Recent acquisitions have grown the company such that, along with improved cash flows, we believe the company can utilise its RCF without stretching its leverage ratios. The post-sale acquisition multiples suggest an attractive valuation in our opinion." |
Posted at 14/5/2025 14:43 by 1jat My viewsCDMO sale looks to be at a good price. CDMO sale provides liquidity to build the business - we can expect £40m to be spent on acquisitions. What these are and price paid will be critical to the future strategy. VLG becomes more focused on product innovation and building distribution relationships. The CDMO outsourcing carries risk of delay and costs that are now outside the group. Margins will have included a manufacturing profit which will leave the business, future margins likely to be less than 48%, more likely 35-40% Looks like VLG is being made more focused as a marketing and product development business which will make it easier to trade its brands, but it remains a set of niche brands/products. Hopefully they can acquire some products will greater potential for scale. Management still incentivised with options on 1m shares each (CEO, CFO) at 39p. The deal looks like they will be in the money. Slater has effective control over the company (can block resolutions /propose Directors) and will be looking for an exit / significant profit. Omens are good. I would like to see the company financial results for the ongoing business. We may need to wait for those. |
Posted at 14/5/2025 07:25 by rivaldo A very thorough article on VLG's deal from the Oak Bloke on Substack. He calculates VLG are on a potential P/E of 3.7 - see his charts/spreadsheets which aren't reproduced here.Here's a couple of brief extracts. He notes that: "if I plug in my 2H24e estimates then I get to a net 33.1p per share of cash on a business you can buy for 50p. A net price of 16.9p. So the business you get for 16.9p net is forecast to generate £66.28m revenue in 2025, although £10.8m of that revenue transfers to Biokosmes, I’m assuming as at 1st July, so an underlying revenue for 2024 of £45m at a 45% gross margin so a £20.2m gross profit. OpEx of -£12m and Amortisation of -£4.5m gets you to £3.7m PBT and £2.8m PAT, that’s 2.2p a share so a P/E of 7.6X (estimated). That’s looking backwards. What if we look forwards? Double-digit growth and a focus on growth combined with cash to invest into marketing and into new market entry should speed up double-digit growth further still. These are my growth estimates for 2025, more or less extrapolating existing growth patterns seen in 2024 and based on known newsflow." "Where a run rate profit based on the 2H25 numbers of around £7.7m annualised (and growing) per year from 2026 appears eminently achievable…. assuming zero further growth from 2H25 mind you :) If you’re happy with that then you’re buying a business able to generate an adj.P/E of 3.7X." VLG "just needs to keep doing what it’s already doing. The 45% sales growth in 2H24 vs 1H24 in my prior article “Full Year Review” is TREMENDOUS! That growth was on products with a 48% average gross margin while the decline in 2H24 was stuff with a ~30% average gross margin - now offloaded in the sale. If we profile the remaining VLG Brands part of the business the four year track record of organic growth is solid too, and the 2025 outlook is attractive. Especially as it also now has a warchest of cash to deploy. Just look at its acquisitions (each row shows the year of acquisition) and then subsequent columns shows the organic growth track record. Do I see a leapord? Well I reckon I’ve spotted a fast cat that’s for sure." |
Posted at 12/5/2025 07:40 by rivaldo Wow. That explains the news hiatus! Looks like extremely good news on the face of it.VLG get £53m for assets with a book value of just £28.9m, so a £24.1m gain, and achieve a sale at 11 times FY24 EBITDA, which seems a very good price indeed. VLG still retain many of their most successful/high potential brands and will grow them accordingly whilst bringing in others, and will have a highly focused business going forward which will be perhaps easier to sell to a larger entity at the right time. |
Posted at 12/5/2025 07:23 by thedudie That is a big transaction! The board have presumably been as frustrated as shareholders at the lowly share price and have decided to do something proactive. Well done to them.There may well have also been pressure from Slater Inv. They must believe there is significant value here or otherwise they wouldn't have been buying so aggressively! |
Posted at 19/2/2025 18:28 by 1jat Camerongd53Slater already has enough shares to have effective control. 24% probably means he can appoint the board and he will be influential in strategic transactions. IDK if there are similar businesses in the Slater stable but if there are, then low premium all share transactions are on the cards. Slater will need an exit (or a substantially better share price) or its fund performance will be affected…̷ We can draw our own conclusions about the building incentives for a potential exit. |
Posted at 04/2/2025 09:32 by sphere25 Had a go at 32.5p. Stop under 32p.This is the issue with VLG. Better to wait for the update because we can never be sure if they're going to hit their numbers. So it is a downgrade with "broadly in line" with expectations. Cavendish: - Revenue £51m (excluding £0.8m from H&H) vs pre-acquisition forecast of £52.5m EBITDA £11.3m vs forecast of £11.7m - They have also cut the forecasts for FY25 pre-tax by 30% due to amortisation, exceptional cost and higher finance cost. - Massaged the report by doing a comparison from FY23 to FY27 with comments on conservative forecasts. Very much needed for VLG! - No dividend There is alot more in there, but this is the thing on how can never be sure what VLG are going to come out with. It is partly why the market moves the way it does with some apprehension here. Sometimes you get exuberant lurches higher but then they get sold into. Yes, the wider market is pants too, but there is still a fair degree of apprehension on consistent target hitting - specifically at VLG. But hey, the forward numbers are interesting and it looks oversold down here. P/E of 5.5, 4.5 and 3.6 over 2025-2027 with respective free cash flow yields of 20%, 22% and 27%. That is juicy enough to keep the market interested. So I have had another go on the back of the latter bullish points rather than the bearish earlier ones. Buying a terrible chart though so I might have to take a little loss if the buying doesn't pick up. But it will stay on the watchlist waiting to see if someone (other than Slater) tries to clear sellers out for some form of stablisation and bullish moves. Last time it had a little pop from around 37p to 40p, but the market closed that key breakout level off with a barrage of selling hitting the book. After that the sellers exhausted Slater and carried on down to these levels. Now we sit and wait to see whether the market can find some bullish boots, even if they are worn and soggy. That is where the bar is right now. It looks cheap. Just all about being clear and consistent on delivery. All imo DYOR |
Posted at 30/12/2024 16:23 by celeritas VLG has plenty of production space to bring many more products in house, hence why they keep buying the odd co now and again while also developing new products.. This drastically cuts costs along with VLG's distribution network.Looking at Health & Her Limited these synergies will play out nicely in 2025 which should move H&H into a healthy net profit. VLG do have a habit of picking these companies up then waiting for net leverage to fall to about 1X before going in again. Slater can see the plan, no doubt he's spoken to directors with the end game being VLG sold with an extensive package of self care products, all under one banner. |
Posted at 31/10/2024 09:40 by rivaldo Excellent new article on the new acquisition from the Oak Bloke:"Conclusion VLG don’t say how much below 1X adj.EBITDA/Debt they foresee being for the end of 2025. I consider only a 9% improvement to profit from 2024 to 2025 and only a 25% improvement to H&H profits is simply too pessimistic. Put it this way the 2 ex-owners of H&H I suspect won’t get their extra £2.5m if the business can only deliver £200k extra profit!!! Beyond that the simple observation I’d also make is that growth in key VLG brands is much higher than 9%, and the headwinds through overstocking which made 1H24 are not recurring. This is my profit model which includes 2025 (me - see the web link). I therefore am going to agree with the “double digits” revenue for H&H combined with just 10% revenue growth for the rest of VLG. Based on a 70/30 split (H&H adds a further chunk to the VLG brands lifting margin) and using a 45% average margin for VLG brands and 32% for Customer I get to a £28.8m GP. Lower interest rates and strong cash generation keeps interest payments below £2m and we therefore see a quadrupling of profit after tax in 2025. So H&H looks complementary to VLG’s buy and build approach. It will help usher in stronger profits in 2025, which on a £55m market cap suggests a P/E of 8.3X. Even a 15X valuation is undemanding - and that places VLG at £100m market cap, nearly double today. Is that perhaps why we saw 115k shares each bought by the Chair and NED today? Is that perhaps why Mark Slater continues to accumulate VLG too?" |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
